



NDA 206111

**NDA APPROVAL**

Boehringer Ingelheim Pharmaceuticals, Inc.  
Attention: Joachim Troost, M.D.  
Senior Associate Director, Regulatory Affairs  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT 06877

Dear Dr. Troost:

Please refer to your New Drug Application (NDA) dated and received August 4, 2014, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Synjardy (empagliflozin and metformin hydrochloride) tablets.

We acknowledge receipt of your amendments dated August 8, October 3, 8, and 9, December 3 and 10, 2014, January 14, 16, 22, and 30, March 2, 11 (2), and 30, April 17, May 12, 21, and 26, June 19, July 2 (2) and August 24, 2015. The submission received on July 2, 2015, constituted a complete response to our June 4, 2015, action letter.

This new drug application provides for the use of Synjardy (empagliflozin and metformin hydrochloride) tablets as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on a regimen containing empagliflozin or metformin, or in patients already being treated with both empagliflozin and metformin.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

**WAIVER OF HIGHLIGHTS SECTION**

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA

automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

### **CARTON AND IMMEDIATE CONTAINER LABELS**

Submit final printed carton and immediate container labels that are identical to the carton and immediate container labels submitted on May 21, 2015, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 206111.**” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages 0 through 9 years (inclusive) because necessary studies are impossible or highly impracticable. This is because there are too few children in this age range with type 2 diabetes mellitus to study.

We are deferring submission of your pediatric studies for ages 10 to 17 years (inclusive) for this application because this product is ready for approval for use in adults and the pediatric studies have not been completed.

Your requirements under the PREA as stated in the approval letter for NDA 204629 for Jardiance (empagliflozin) tablets, dated August 1, 2014, also apply to NDA 206111. We refer to our June 19, 2015, letter granting deferral extension of PMR 2755-1, (b) (4). Accordingly, your requirements under the PREA are as follows:

2755-1 A single-dose pharmacokinetic and pharmacodynamics trial of empagliflozin in pediatric patients 10 to 17 years (inclusive) with type 2 diabetes mellitus.

Study Completion: June 2015  
Final Report Submission: December 2016

2755-2 A 24-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of empagliflozin for the treatment of pediatric patients 10 to 17 years (inclusive) with type 2 diabetes mellitus as an add-on to metformin, followed by a 28-week double-blind, placebo- or active-controlled extension period. The efficacy and safety study should have at least 30% of randomized subjects 10 to 14 years (inclusive) of age and at least one-third (but not more than two-thirds) of subjects in both age subsets (10 to 14 years [inclusive] and 15 to 17 [inclusive]) will be female. Secondary safety endpoints should include the effect of empagliflozin on mineral and bone metabolism, and the effect of empagliflozin on growth. This trial should not be initiated until after the data from the juvenile animal study have been submitted to and reviewed by the Agency.

Final Protocol Submission: November 2015  
Study Completion: February 2019  
Final Report Submission: August 2019

2755-3 A study to evaluate empagliflozin toxicity in juvenile rats.

Study Completion: November 2014  
Final Report Submission: May 2015

Submit the protocols to your IND 102145, with a cross-reference letter to NDA 204629 and to this NDA.

Reports of these required pediatric postmarketing studies must be submitted as a new drug application (NDA) or as a supplement to your approved NDA with the proposed labeling changes you believe are warranted based on the data derived from these studies. When submitting the reports, please clearly mark your submission “**SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS**” in large font, bolded type at the beginning of the cover letter of the submission.

Please cross-reference this NDA when you submit your final reports for requirements 2755-1, 2755-2, and 2755-3 to NDA 204629.

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Michael G. White, Ph.D., Regulatory Project Manager, at (240) 402-6149.

Sincerely,

*{See appended electronic signature page}*

Jean-Marc Guettier, M.D.  
Director  
Division of Metabolism and Endocrinology Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

Enclosures:

Content of Labeling  
Carton and Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

JEAN-MARC P GUETTIER  
08/26/2015